larg
number
escherichia
coli
yeast
recombin
protein
initi
employ
first
solidphas
protein
array
largescal
product
recombin
protein
requir
signific
time
effort
product
process
introduc
variou
problem
later
influenc
perform
protein
immunoassay
studi
larg
number
proteincod
sequenc
clone
appropri
express
vector
express
bacteria
yeast
recombin
protein
isol
lysat
use
affin
tag
glutathionestransferas
gst
purifi
glutathioneaffin
support
owe
fact
recombin
protein
extract
contain
variabl
amount
e
coli
contamin
purif
serum
sampl
test
must
preincub
bacteri
yeast
lysat
block
nonspecif
bind
addit
block
agent
typic
need
decreas
background
increas
signaltonois
ratio
owe
toxic
express
protein
insolubl
issu
recombin
protein
gener
bacteria
yeast
often
show
variabl
express
low
yield
result
mark
differ
antigen
coat
effici
yield
fals
neg
andor
miss
detect
antigen
protein
array
highli
use
identifi
antigen
target
unbias
fashion
complex
proteom
one
studi
largescal
pathogen
antibodi
profil
involv
gener
recombin
e
coliproduc
protein
treponema
pallidum
caus
agent
syphili
differ
protein
produc
gst
tag
directli
immobil
onto
glutathioneco
microtit
plate
elisa
test
approxim
pallidumprotein
target
antibodi
palliduminfect
rabbit
followup
studi
use
sera
syphilisinfect
patient
differ
pallidum
antigen
array
microtit
plate
use
antibodi
profil
total
addit
protein
found
antigen
infect
patient
antibodi
respons
vari
primari
secondari
latent
syphili
infect
one
identifi
protein
studi
later
found
protect
antigen
experiment
infect
rabbit
antibodi
array
profil
technolog
provid
new
inform
monitor
understand
respons
vaccin
exampl
antibodi
respons
simian
model
human
hiv
infect
evalu
use
combin
distinct
recombin
protein
chemic
synthes
short
peptid
select
protein
polyllysineco
microscop
slide
use
spot
differ
recombin
peptid
antigen
serum
sampl
macaqu
vaccin
three
differ
hiv
multiprotein
vaccin
well
siv
viral
challeng
analyz
follow
incub
sera
secondari
antibodi
use
detect
primari
antibodi
bind
fluoresc
scan
bcell
respons
gener
array
data
distinguish
vaccin
macaqu
viruschalleng
macaqu
immunoreact
sever
peptid
epitop
also
predict
surviv
interestingli
analysi
bcell
respons
three
differ
multiprotein
vaccin
reveal
converg
immunodomin
antibodi
respons
sever
linear
epitop
envelop
protein
largescal
analysi
afford
protein
array
studi
enabl
identif
epitop
would
possibl
elisa
western
blot
protein
array
use
recombin
antigen
produc
yeast
also
use
diagnosi
sar
studi
open
read
frame
orf
entir
proteom
sar
coronaviru
sever
protein
relat
coronavirus
amplifi
pcr
clone
yeast
express
vector
produc
viral
protein
ctermin
gst
fusion
follow
purif
antigen
gstaffin
chromatographi
recombin
fusion
protein
spot
nitrocelluloseco
slide
probe
array
serum
antibodi
sarsinfect
patient
distinguish
healthi
control
demonstr
diagnost
potenti
approach
sidebysid
comparison
microarray
diagnost
elisa
sar
show
assay
format
yield
similar
result
studi
demonstr
array
employ
vitroproduc
recombin
protein
use
discov
new
antigen
identifi
vaccin
target
monitor
vaccin
outcom
diagnost
larg
number
immunodomin
antigen
epitop
identifi
screen
solidphas
array
exhibit
similar
analyt
sensit
elisa
like
miss
mani
conform
epitop
protein
array
similar
elisa
also
suffer
limit
dynam
rang
dynam
rang
best
one
major
impedi
use
approach
signific
labor
resourc
produc
larg
number
purifi
recombin
antigen
produc
vivo
bacteri
yeast
express
system
altern
vivo
product
recombin
protein
antigen
array
also
produc
use
vitro
transcriptiontransl
ivtt
felgner
group
develop
rel
simpl
scalabl
pcrbase
recombin
approach
gener
necessari
antigen
express
vector
construct
compat
ivtt
express
construct
use
produc
recombin
protein
via
cellfre
e
coliivtt
reaction
unpurifi
recombin
protein
print
nitrocellulos
array
sinc
recombin
protein
produc
cellfre
system
gener
e
coli
compon
also
bind
array
matrix
sera
must
first
block
bacteri
lysat
incub
array
follow
array
incub
sera
fluoresc
label
secondari
antibodi
use
detect
primari
antibodi
bind
largescal
screen
experi
identifi
larg
number
antigen
protein
varieti
human
infecti
agent
includ
vaccinia
viru
francisella
tularensi
chlamydia
trachomati
plasmodium
falciparum
coxiella
burnetii
burkholderia
pseudomallei
davi
et
al
first
demonstr
feasibl
ivtt
largescal
antigen
array
identifi
new
antigen
target
unbias
fashion
studi
vaccinia
viru
antigen
test
sera
natur
infect
anim
human
new
antigen
target
identifi
one
antigen
envelop
protein
later
identifi
major
target
neutral
antibodi
associ
smallpox
vaccin
addit
test
sera
vaccinia
infect
smallpox
vaccinia
vaccin
licens
smallpox
vaccin
archiv
convalesc
smallpox
sera
reveal
similar
antibodi
profil
varieti
antigen
envelop
core
protein
identifi
potenti
target
vaccin
monitor
analysi
antibodi
signal
posit
neg
antigen
reveal
rel
narrow
dynam
rang
fluoresc
intens
show
titer
differ
nevertheless
approach
use
identifi
immunodomin
antigen
within
viral
proteom
unbias
fashion
immunodomin
antigen
also
identifi
potenti
target
vaccin
malaria
pfalciparum
protein
gener
ivtt
print
microarray
slide
studi
antibodi
respons
natur
experiment
malari
infect
antibodyprofil
experi
highli
reactiv
antigen
might
repres
malaria
vaccin
target
provid
new
inform
immun
correl
vaccin
protect
identifi
wheat
germ
rather
e
coli
ivtt
also
use
studi
malaria
vaccin
antigen
candid
one
major
bottleneck
gener
recombin
protein
need
clone
code
sequenc
orf
express
vector
plasmid
use
ivtt
even
faster
less
laborintens
approach
call
transcript
activ
pcr
tap
also
use
prime
site
transcript
machineri
ivtt
directli
incorpor
pcr
primer
one
studi
tap
fragment
produc
recombin
p
falciparum
antigen
microarray
spot
good
standard
plasmidclon
approach
thu
tap
extend
versatil
ivtt
array
technolog
rapidli
gener
larg
number
recombin
protein
array
print
studi
also
success
employ
ivtt
antigen
array
demonstr
abil
approach
detect
subtl
differ
humor
respons
candid
vaccin
natur
exposur
molina
et
al
use
antigen
array
studi
c
trachomati
use
mice
inocul
live
uvinactiv
chlamydia
studi
array
protein
seven
immunodomin
antigen
could
develop
vaccin
target
identifi
immunoglobulin
subtypespecif
antibodi
profil
also
differ
live
uvinactiv
chlamydia
therebi
elucid
humor
respons
differ
two
experiment
vaccin
strategi
array
approach
distinguish
live
versu
uvinactiv
chlamydia
suggest
array
technolog
could
use
monitor
subtl
respons
vaccin
anoth
major
find
largescal
array
antibodi
profil
global
insight
antigen
protein
differ
subcellular
local
case
intracellular
bacteria
f
tularensi
surfac
membraneassoci
protein
antigen
compar
entir
proteom
global
antibodyprofil
studi
highlight
rel
antigen
differ
type
protein
identifi
new
antigen
could
exploit
diagnost
purpos
anoth
studi
potenti
antigen
orf
borrelia
burgdorfi
caus
agent
lyme
diseas
studi
ivtt
antigen
array
sera
patient
earli
late
diseas
overal
orf
found
antigen
comparison
human
antigen
profil
deer
mice
natur
host
reservoir
show
similar
antibodi
profil
suggest
common
set
immunogen
differ
host
similar
largescal
screen
b
pseudomallei
protein
identifi
diseasespecif
antigen
well
antigen
crossreact
healthi
individu
probabl
reflect
share
antigen
bacteri
protein
largest
protein
antigen
screen
date
orf
c
burnetii
agent
respons
q
fever
gener
array
analysi
approxim
protein
identifi
antigen
may
form
basi
simpl
serodiagnost
immunoassay
need
pathogen
overal
inform
insight
largescal
antibodyprofil
studi
uniqu
array
provid
multipl
area
followup
includ
diagnost
identifi
vaccin
target
understand
host
respons
global
protein
repertoir
pathogen
organ
larg
amount
inform
obtain
antigen
array
studi
sever
limit
exampl
observ
differ
antibodi
immunoreact
may
due
variat
amount
protein
immobil
rather
actual
serum
antibodi
titer
differ
one
approach
direct
improv
ivtt
antigen
array
develop
nucleic
acid
programm
protein
array
nappa
format
recombin
protein
also
gener
ivtt
antigen
immobil
situ
mean
fuse
epitop
tag
exampl
ctermin
gsttag
protein
captur
directli
nappa
immobil
glutathion
approach
elimin
need
express
purifi
protein
separ
sinc
immobil
ivtt
reaction
strategi
elimin
potenti
stabil
issu
provid
greater
puriti
target
antigen
necessari
presenc
gst
moieti
also
allow
array
probe
antigst
antibodi
estim
amount
protein
immobil
array
one
nappa
studi
antigen
pseudomona
aeruginosawer
produc
profil
sera
cystic
fibrosi
patient
patient
acut
infect
studi
outer
membran
protein
p
aeruginosawer
determin
highli
antigen
target
immunoreact
antigen
array
also
detect
sera
healthi
individu
probabl
reflect
antibodi
direct
homolog
protein
bacteria
regard
array
yersinia
pesti
also
detect
antibodi
crossreact
rabbit
immun
sever
differ
gramneg
bacteria
togeth
find
suggest
mani
antigen
epitop
share
among
similar
protein
differ
gramneg
bacteria
consist
known
protein
sequenc
mani
bacteria
howev
clear
detect
antibodi
conform
epitop
immunoassay
format
might
better
distinguish
respons
protein
differ
bacteria
conclus
protein
array
extrem
power
tool
antigen
discoveri
provid
antibodi
respons
data
thousand
protein
possibl
use
technolog
howev
antigen
array
probabl
less
practic
diagnost
slow
solidphas
assay
requir
block
serum
probabl
underestim
breadth
strength
humor
respons
ie
antibodi
titer
show
differ
limit
dynam
rang
also
may
constrict
rel
differ
immunoreact
certain
antigen
addit
protein
array
microspher
immunoassay
technolog
luminex
corp
tx
usa
also
use
detect
measur
multipl
antibodi
given
sampl
studi
solidphas
bead
differentcolor
fluorophor
use
immobil
differ
antigen
follow
incub
sera
fluoresc
secondari
antibodi
use
sampl
pass
detector
one
laser
excit
fluorochrom
bead
exhibit
uniqu
signal
laser
excit
fluoresc
molecul
eg
phycoerythrin
bound
second
antibodi
thu
antigen
ident
bead
fluoresc
antibodi
titer
secondari
antibodi
fluoresc
obtain
simultan
approxim
differ
microspher
avail
potenti
allow
multipl
antigen
detect
sever
studi
use
multiplex
luminex
assay
detect
antibodi
differ
pathogen
includ
papillomaviru
bordetella
pertussi
clostridium
tetani
corynebacterium
diphtheria
haemophilu
influenza
type
b
studi
detect
multipl
differ
pathogen
primari
goal
one
intrins
problem
luminex
suffici
quantiti
purifi
antigen
need
must
coval
coupl
bead
altern
ivvt
protein
use
epitop
antiepitop
tag
luminex
immobil
concentr
studi
antibodi
sever
differ
viru
ebv
protein
detect
use
luminexbas
assay
howev
antiebv
antibodi
signal
best
fivefold
background
vector
control
thu
level
detect
antiebv
antibodi
respons
narrow
rang
detect
limit
util
technolog
obtain
detail
antigen
profil
understand
full
rang
antibodi
respons
pathogen
recent
waterbo
et
al
document
anoth
intrins
problem
luminex
technolog
serolog
assay
human
sera
found
directli
bind
carboxyl
microspher
caus
fals
posit
high
level
nonspecif
background
recent
studi
show
altern
microspher
luminex
corp
tx
usa
improv
block
protocol
reduc
nonspecif
bind
problem
final
need
prepar
antigenspecif
captur
bead
along
cost
expertis
need
run
flow
cytometri
machin
thu
far
limit
technolog
mainli
profil
antibodi
differ
infecti
agent
singl
multiplex
luminex
assay
run
addit
studi
antibodi
infecti
agent
detect
autoantibodi
selfprotein
extrem
import
predict
diagnos
monitor
autoimmun
diseas
probabl
diseas
cancer
solutionphas
immunoassay
radiobind
assay
rba
often
show
highest
sensit
specif
detect
autoantibodi
autoimmun
diseas
rba
detect
mani
conform
epitop
solidphas
immunoassay
assay
choic
detect
low
highaffin
antibodi
autoantigen
result
high
sensit
specif
rba
use
radiolabel
antigen
gener
typic
ivtt
solutionphas
immunoprecipit
assay
exampl
rba
varieti
human
pancreat
target
includ
use
predict
diagnos
monitor
autoantibodi
type
diabet
note
rba
method
detect
autoantibodi
show
high
sensit
specif
date
protein
array
show
high
degre
diagnost
perform
furthermor
rba
also
show
much
larger
dynam
rang
titer
solidphas
immunoassay
make
use
accur
evalu
antibodi
titer
unfortun
applic
rba
receiv
littl
attent
monitor
antibodi
infecti
agent
mainli
requir
radioact
protein
label
discuss
next
section
power
altern
nonradioact
solutionphas
assay
luciferas
immunoprecipit
system
lip
luciferas
immunoprecipit
system
har
lightemit
recombin
antigenfus
protein
quantit
measur
patient
antibodi
titer
renillaluciferas
ruc
deriv
sea
pansi
use
gener
antigen
fusion
ruc
ideal
report
owe
small
size
ie
molecular
weight
kda
approxim
size
green
fluoresc
protein
wide
linear
detect
rang
light
unit
lu
complet
lack
antigen
human
anim
sera
luciferas
includ
firefli
luciferas
also
use
lip
antigen
fusion
ctermin
ruc
made
clone
vector
vector
gener
ntermin
fusion
sinc
better
yield
luciferasetag
protein
often
observ
antigen
comparison
express
vector
usual
reserv
cell
surfac
receptor
associ
protein
well
secret
protein
burbelo
pd
unpublish
data
secret
protein
remov
signal
peptid
clone
antigen
ctermin
fusion
suffici
allow
proper
conform
fold
exposur
antigen
epitop
target
remov
signal
sequenc
produc
antigen
ctermin
fusion
result
poor
antigen
redesign
target
ntermin
fusion
protein
vector
test
well
exampl
antibodi
detect
conform
neutral
antibodi
within
ebv
extracellular
protein
work
better
protein
clone
rather
rucantigen
mammalian
express
plasmid
gener
construct
transient
transfect
cell
eg
hek
produc
ruc
antigen
h
transfect
cell
scrape
cold
lysi
buffer
contain
glycerol
clear
centrifug
use
directli
lip
assay
altern
extract
store
frozen
typic
remain
stabl
least
month
without
purif
cell
lysat
contain
directli
tag
ruc
antigen
use
lip
evalu
antibodi
contrast
protein
array
highthroughput
lip
format
detect
antibodi
mani
differ
serum
sampl
one
target
given
assay
howev
eas
ruc
antigen
gener
lip
format
easili
scalabl
screen
hundr
serum
sampl
multipl
antigen
studi
master
microtit
plate
serum
particular
patient
cohort
first
made
master
plate
use
dispens
dilut
serum
sampl
individu
test
plate
allow
reiter
profil
sera
antibodi
profil
gener
antigen
duplic
use
serum
per
patient
sinc
ruc
report
linear
dynam
rang
case
need
dilut
sera
accur
quantifi
antibodi
first
step
lip
involv
incub
serum
contain
antibodi
rucantigen
lysat
togeth
room
temperatur
h
although
rare
necessari
increas
antibodi
bind
also
achiev
incub
incub
sera
mixtur
transfer
microtit
filter
plate
contain
protein
ag
bead
addit
hour
captur
free
immunoglobulin
complex
captur
antibodi
highbindingcapac
protein
ag
bead
mg
immunoglobulin
bind
per
millilit
bead
microtit
filter
plate
use
prefer
magnet
protein
ag
bead
lower
cost
higher
bind
effici
protein
ag
bead
effici
immunoprecipit
igg
antibodi
poorli
detect
iga
igm
antibodi
immunoglobulin
subtyp
also
examin
use
lip
requir
special
affin
reagent
exampl
lip
detect
antibodi
sera
filarialinfect
patient
coupl
secondari
antibodi
bead
develop
determin
isotypespecif
antibodi
antiigm
iga
ige
may
use
incub
complex
protein
ag
bead
filter
plate
extens
rins
wash
buffer
remov
unbound
ructag
antigen
although
manual
wash
suction
use
vacuum
manifold
perform
wash
easili
accomplish
aid
robot
workstat
plate
washer
vacuum
filtrat
filtrat
filter
plate
load
plate
luminomet
equip
substrat
injector
use
lip
highli
quantit
antibodi
titer
valu
report
lu
assign
clinic
experiment
serum
sampl
lip
test
low
lu
reflect
presenc
antibodi
elev
lu
reflect
high
antibodi
titer
unlik
immunoassay
lip
titer
valu
often
compar
use
geometr
mean
titer
gmt
wide
dynam
rang
overdispers
natur
lip
data
typic
repres
scale
cutoff
determin
use
mean
plu
standard
deviat
sd
control
group
contrast
solidphas
assay
diagnost
perform
use
either
mean
plu
sd
cutoff
gener
ident
much
greater
analyt
sensit
lip
final
compar
solidphas
assay
even
solutionphas
rba
lip
show
greater
dynam
rang
reflect
higher
signaltonois
ratio
owe
low
background
high
signal
lip
test
ideal
develop
diagnost
use
singl
antigen
furthermor
larg
dynam
rang
antibodi
titer
within
seroposit
rang
addit
clinic
util
accur
assess
differ
stage
infect
substratifi
diseas
monitor
vaccin
treatment
illustr
high
diagnost
perform
lip
describ
sever
exampl
singleantigen
lip
test
extrem
robust
featur
high
diagnost
sensit
specif
one
exampl
lip
use
antibodi
profil
diagnosi
herp
simplex
viru
hsv
infect
gold
standard
detect
antibodi
diagnosi
western
blot
lip
test
singl
rucantigen
fusion
gener
highli
robust
antibodi
titer
infect
sampl
higher
neg
sampl
exampl
geometr
mean
seroneg
sampl
lu
versu
lu
sampl
importantli
lip
assay
correl
perfectli
western
blot
analysi
sensit
specif
contrast
elisa
show
sensit
specif
highli
quantit
antibodi
titer
sever
envelop
structur
protein
also
detect
use
studi
natur
infect
vaccin
monitor
anoth
exampl
high
diagnost
perform
singleantigen
lip
test
loa
loa
filari
infect
occur
mainli
africa
asia
lip
test
measur
antibodi
readili
differenti
l
loainfect
uninfect
patient
demonstr
markedli
improv
sensit
specif
compar
exist
elisa
sensit
specif
signific
crossimmunoreact
antibodi
observ
filari
infect
measur
antibodi
show
signific
correl
antiigg
result
show
advantag
measur
total
igg
respons
alon
result
demonstr
high
diagnost
perform
achiev
lip
use
singl
antigen
serolog
test
b
burgdorfi
infect
spirocyt
respons
lyme
diseas
need
diagnos
monitor
antibiot
treatment
lyme
diseas
lip
screen
panel
b
burgdorfi
antigen
reveal
high
antibodi
titer
number
antigen
differ
infect
patient
also
show
mark
patient
heterogen
burbelo
pd
issa
ching
kh
cohen
ji
iadarola
mj
marqu
unpublish
data
howev
achiev
highest
sensit
synthet
gene
synthesi
approach
use
small
synthet
protein
design
vovo
consist
repeat
antigen
vlseospcvlseospc
immunodomin
peptid
vovo
lip
test
show
sensit
specif
burbelo
pd
issa
ching
kh
cohen
ji
iadarola
mj
marqu
unpublish
data
similarli
establish
elisa
show
sensit
specif
unlik
elisa
vovo
lip
test
display
wide
dynam
rang
antibodi
detect
span
without
serum
dilut
find
suggest
lip
screen
use
vovo
b
burgdorfi
antigen
offer
effici
quantit
approach
evalu
antibodi
respons
lyme
diseas
moreov
synthet
recombin
approach
use
lip
may
highli
use
diagnosi
studi
antibodi
respons
pathogen
protein
summari
lip
repres
univers
format
develop
diagnost
test
mani
infecti
agent
appeal
aspect
lip
substanti
gap
highest
titer
valu
neg
sera
lowest
titer
valu
posit
sera
mani
antigen
test
make
possibl
predict
infect
statu
given
serum
without
previous
determin
cutoff
valu
train
set
sampl
lip
also
requir
signific
assay
optim
obtain
highqual
antibodi
titer
data
owe
characterist
like
mani
novel
antigen
identifi
array
technolog
particularli
area
diagnosi
monitor
vaccin
could
evalu
use
lip
technolog
increas
interest
understand
antibodi
respons
whole
proteom
differ
infecti
agent
studi
use
solidphas
antigen
array
underestim
breadth
strength
antibodi
respons
use
lip
larger
dynam
rang
antibodi
titer
detect
mani
conform
immunoassay
provid
highdefinit
antibodi
profil
exampl
lip
use
gener
highdefinit
antibodi
profil
entir
proteom
hiv
hivinfect
patient
total
differ
hiv
protein
test
includ
process
hiv
protein
chronic
hivinfect
patient
robust
antibodi
titer
detect
least
one
hiv
protein
least
one
infect
patient
case
multipl
antigen
immunoreact
detect
mani
antibodi
titer
detect
lip
antigen
higher
hivinfect
patient
compar
uninfect
subject
antigen
hiv
protein
show
similar
antibodi
titer
hiv
patient
test
might
expect
antibodi
differ
protein
fragment
eg
nc
process
gag
protein
show
similar
high
titer
patient
test
addit
antibodi
also
detect
sever
small
nonstructur
protein
includ
tat
rev
vpr
vpu
patient
owe
larg
dynam
rang
titer
valu
typic
obtain
lip
hiv
infecti
agent
flame
heatmap
typic
use
graphic
visual
antibodi
profil
multipl
antigen
differ
infect
control
sampl
simultan
heatmap
antibodi
titer
rang
lu
graphic
present
use
color
palett
rang
green
red
reflect
nolow
high
antibodi
titer
respect
analysi
antibodi
respons
heatmap
data
often
mark
heterogen
patient
immunoreact
larg
panel
antigen
studi
underway
use
full
hiv
proteom
respons
substratifi
infect
patient
base
clinic
symptom
length
infect
paramet
like
antibodi
profil
antigen
hiv
pathogen
could
yield
signific
insight
patient
complic
prognosi
monitor
respons
therapi
along
line
recent
lip
profil
patient
reveal
antihcv
antibodi
respons
biomark
respons
therapi
final
rel
simplic
lip
technolog
make
practic
small
laboratori
gener
antibodi
respons
profil
infecti
agent
rel
small
proteom
ie
protein
moreov
lip
use
screen
immunodomin
antigen
diagnost
test
sinc
need
sensit
specif
test
identifi
human
herp
viru
hhv
sarcoma
ks
associ
virusinfect
individu
especi
among
potenti
blood
donor
lip
use
identifi
diagnost
use
antigen
panel
differ
fusion
protein
includ
varieti
latent
lytic
antigen
test
serum
patient
ks
lip
test
protein
show
weak
nonexist
antibodi
titer
ks
sera
howev
latent
protein
vcyclin
highli
antigen
approxim
ks
sampl
antibodi
titer
ks
sampl
higher
uninfect
control
result
contrast
report
use
number
bacteri
produc
gst
fusion
western
blot
unabl
detect
immunoreact
vcyclin
detect
diagnost
use
antibodi
vcyclin
lip
bacteri
recombin
protein
western
blot
support
notion
lip
antigen
may
detect
mani
conform
epitop
part
recombin
protein
test
solut
mild
condit
particularli
use
diagnosi
infect
find
posit
antivcyclin
antibodi
respons
detect
sera
determin
neg
elisa
andor
lip
antibodi
antigen
togeth
studi
demonstr
lip
effect
yet
simpl
rapid
method
screen
protein
proteom
infecti
agent
identifi
diagnost
use
antigen
elisa
employ
singl
antigen
use
diagnosi
infect
often
detect
antibodi
one
antigen
suffici
high
diagnost
sensit
hla
differ
among
subject
differ
diseas
stage
variabl
circumv
problem
multipl
elisa
detect
differ
antibodi
differ
antigen
run
parallel
follow
data
analysi
exampl
optim
serolog
diagnosi
infect
elisa
involv
analyz
result
two
three
antigen
effort
simplifi
test
elisa
format
coat
multipl
antigen
microtit
plate
usual
unsuccess
antigen
coat
effici
quit
variabl
result
poor
diagnost
perform
altern
multiepitop
hybrid
recombin
molecul
employ
wherebi
multipl
antigen
immunodomin
region
fuse
togeth
singl
protein
hybrid
antigen
highli
use
time
effort
requir
design
optim
perform
altern
approach
run
multipl
individu
assay
mixtur
multipl
ruc
antigen
test
simultan
lip
protein
ag
bead
captur
subset
immunoglobulin
present
serum
allow
multipl
ruc
antigen
immunoprecipit
simultan
protein
ag
bead
analysi
data
also
simplifi
lip
mixtur
format
exampl
mixtur
four
antigen
contain
lana
vcyclin
show
sensit
specif
detect
infect
ks
patient
lip
antigen
mixtur
test
also
highli
success
diagnos
infect
twoantigen
lip
mixtur
strongyloid
stercorali
diagnosi
fourantigen
lip
mixtur
onchocerciasi
diagnosi
fourantigen
lip
mixtur
cytomegaloviru
diagnosi
show
higher
diagnost
perform
elisabas
test
sinc
mixtur
approach
simpl
base
use
inform
singleantigen
test
probabl
use
gener
approach
diagnosi
mani
infect
diseas
state
given
larg
rang
antibodi
titer
detect
lip
technolog
ideal
explor
antibodi
profil
stratifi
differ
clinic
featur
caus
infecti
agent
one
lip
studi
antibodi
two
latent
two
lytic
antigen
examin
three
differ
diseas
caus
virus
ks
two
lymphoprolifer
disord
multicentr
castleman
diseas
mcd
primari
effus
lymphoma
pel
one
obviou
differ
antibodi
titer
earli
lytic
antigen
markedli
higher
pel
mcd
patient
compar
ks
patient
contrast
antibodi
profil
markedli
higher
antibodi
vcyclin
latent
gene
found
ks
pel
patient
compar
mcd
patient
sinc
elev
antilat
antibodi
common
featur
found
ks
patient
compar
mcd
sum
antivcyclin
antilana
antibodi
use
approach
optim
segreg
ks
mcdk
mcdk
approach
use
set
cutoff
valu
discrimin
ks
mcdk
sensit
specif
result
demonstr
lip
provid
uniqu
inventori
clinic
relev
antibodi
respons
like
would
miss
technolog
anoth
studi
lip
use
profil
antibodi
human
tcell
lymphotrop
viru
type
infect
sinc
small
subset
individu
develop
adult
tcell
leukemia
atll
myelopathytrop
spastic
paraparesi
hamtsp
antibodi
profil
examin
see
differ
diseas
state
could
distinguish
analysi
antibodi
titer
data
seven
differ
protein
reveal
antigag
antibodi
titer
inform
distinguish
htlvinfect
subject
uninfect
control
show
sensit
specif
howev
antigag
antibodi
titer
similar
asymptomat
atll
hamtsp
subgroup
contrast
antienv
antibodi
titer
fourfold
higher
hamtsp
compar
asymptomat
p
atll
patient
p
antienv
antibodi
asymptomat
carrier
r
correl
well
provir
load
antibodi
anoth
protein
tax
also
higher
hamtsp
compar
asymptomat
control
overal
studi
indic
antibodi
respons
detect
lip
use
diagnosi
suggest
elev
antienv
antibodi
common
featur
found
hamtsp
patient
studi
studi
highlight
fact
lip
employ
sensit
distinguish
differ
diseas
state
caus
possibl
infecti
agent
need
develop
rapid
person
serumbas
diagnost
test
detect
autoimmun
cancer
infecti
diseas
type
pointofcar
diagnost
could
extrem
valuabl
clinic
set
sever
rapid
antibodybas
test
alreadi
develop
test
mainli
yield
qualit
seroneg
seroposit
statu
exampl
later
flow
immunoassay
use
diagnosi
sever
infecti
agent
hiv
hcv
produc
qualit
result
ie
posit
neg
yield
inform
data
antibodi
titer
clinician
owe
rapid
kinet
solutionphas
assay
lip
ideal
develop
quantit
pointofcar
test
end
lip
use
modifi
rapid
format
call
quick
lip
qlip
diagnos
infect
autoimmun
qlip
test
min
total
process
time
per
serum
sampl
need
includ
setup
two
incub
step
min
wash
read
plate
luminomet
even
faster
determin
possibl
equip
rapid
liquid
handl
nevertheless
two
differ
qlip
test
shown
promis
diagnosi
infect
l
loa
onchocerciasi
studi
qlip
inform
normal
lip
format
markedli
better
elisa
addit
compar
qlip
lip
detect
autoantibodi
diagnosi
syndrom
autoimmun
diseas
character
inflamm
salivari
lacrim
gland
high
level
autoantibodi
protein
la
qlip
abl
rapidli
sensit
detect
antibodi
often
higher
syndrom
patient
control
futur
improv
instrument
need
move
qlip
test
handheld
devic
offic
field
test
almost
vaccin
elicit
robust
antibodi
respons
correl
extent
protect
afford
vaccin
measur
antibodi
respons
typic
made
elisa
viru
neutral
assay
neutral
antibodi
recogn
conform
epitop
poorli
detect
elisa
solidphas
assay
contrast
solutionphas
lip
assay
readili
detect
conform
epitop
current
assay
studi
antibodymedi
neutral
ebv
typic
requir
week
perform
labor
intens
sashihara
et
al
use
lip
measur
antibodi
respons
two
ebv
surfac
glycoprotein
particular
interest
ideal
candid
vaccin
target
involv
ebv
attach
fusion
b
lymphocyt
respect
interestingli
lip
antibodi
titer
correl
strongli
r
neutral
activ
measur
standard
transformationbas
assay
note
previou
elisa
studi
report
antibodi
correl
neutral
activ
first
time
antibodi
also
detect
lip
antibodi
titer
partial
correl
neutral
activ
result
demonstr
potenti
simpl
rapid
lip
assay
monitor
antibodi
possibl
conform
epitop
miss
elisa
assess
neutral
activ
addit
yield
insight
conformationspecif
antibodi
highli
quant
lip
assay
allow
detect
subtl
antibodi
titer
differ
elicit
differ
vaccin
strategi
lip
use
monitor
antibodi
test
effect
attenu
singlesubunit
vaccin
guinea
pig
model
hsv
anim
vaccin
attenu
viru
well
singl
recombin
subunit
vaccin
surfac
glycoprotein
administ
two
differ
adjuv
vaccin
lip
detect
induct
antibodi
three
differ
surfac
protein
delet
vaccin
addit
statist
signific
differ
antibodi
titer
detect
anim
receiv
complet
incomplet
freund
adjuv
cfaifa
compar
receiv
alummpl
howev
anim
receiv
alummpl
antibodi
titer
detect
lip
correl
activ
result
demonstr
intric
vaccin
antibodi
respons
teas
use
highli
quant
antibodi
profil
lip
luciferas
immunoprecipit
system
also
use
monitor
antibodi
respons
major
influenza
vaccin
antigen
target
develop
therapeut
vaccin
avian
influenza
studi
doseescal
clinic
trial
use
inactiv
vaccin
administ
healthi
volunt
two
differ
process
form
surfac
hemagglutinin
ha
test
lip
interestingli
high
level
detect
mani
individu
vaccin
day
possibl
crossreact
influenza
conserv
across
influenza
speci
contrast
antibodi
titer
gener
absent
day
dramat
increas
individu
follow
vaccin
interestingli
sever
subject
show
robust
antibodi
increas
longitudin
vaccin
seri
show
immun
respons
microneutr
assay
promis
result
vaccin
studi
futur
work
addit
ntermin
fusion
may
hold
greater
promis
correct
fold
detect
surrog
neutral
antibodi
could
easili
test
lip
lastli
result
also
highlight
even
lip
correct
fold
given
cell
surfac
target
may
optim
may
requir
test
multipl
differ
construct
obtain
protein
nativ
conform
varieti
immunoassay
format
avail
profil
antibodi
larg
panel
antigen
solidphas
array
technolog
increasingli
use
understand
antibodi
respons
whole
proteom
develop
new
candid
vaccin
use
ivtt
gain
particular
attent
rather
use
recombin
protein
made
vivo
bacteria
yeast
ivtt
provid
rel
rapid
simpl
approach
gener
need
recombin
protein
protein
array
use
protein
array
possibl
profil
antibodi
respons
protein
given
pathogen
often
protein
one
time
futur
protein
array
allow
simultan
studi
antibodi
differ
pathogen
addit
expans
avail
protein
array
lip
technolog
also
continu
grow
owe
high
diagnost
perform
lip
use
one
immunodomin
antigen
mixtur
format
may
possibl
develop
lip
test
known
human
pathogen
bacteria
fungi
protozoa
filari
nematod
virus
applic
largescal
screen
pathogen
antibodi
patient
undiagnos
diseas
may
yield
insight
clinic
condit
addit
comprehens
resourc
could
also
develop
pointofcar
test
could
greatli
enhanc
diagnosi
wide
varieti
infecti
agent
abil
monitor
vaccin
strength
sophist
clone
strategi
could
greatli
enhanc
mani
lip
studi
exampl
recombin
approach
use
tap
system
lip
could
greatli
enhanc
product
need
antigen
target
sinc
lip
highthroughput
protein
array
identifi
new
antigen
protein
array
studi
antigen
lip
may
effici
way
develop
antibodybas
test
diagnosi
infect
monitor
respons
vaccin
lastli
antibodi
inventori
gener
technolog
may
also
integr
type
highthroughput
inform
includ
tcell
respons
genom
proteom
data
system
level
analysi
although
discuss
addit
autoantibodi
profil
human
protein
may
also
studi
parallel
could
provid
inform
regard
studi
advers
reaction
due
vaccin
expect
next
year
antibodi
profil
gener
protein
array
lip
technolog
continu
provid
import
inform
diagnosi
antigen
discoveri
vaccin
monitor
understand
infecti
diseas
pathogenesi
although
overal
knowledg
humor
respons
full
proteom
infecti
agent
still
limit
technolog
provid
use
resourc
year
come
abil
technolog
perform
largescal
antibodi
screen
also
help
acceler
studi
newli
discov
pathogen
sinc
detect
host
humor
respons
infecti
agent
provid
indirect
evid
vivo
express
pathogen
abil
rapidli
comprehens
gener
multipl
recombin
protein
given
pathogen
use
epidemiolog
studi
confirm
relationship
exposur
infect
diseas
pathogenesi
antibodi
profil
also
allow
explor
variou
human
diseas
state
exposur
pathogen
contribut
trigger
subsequ
patholog
disord
final
like
addit
modif
exist
approach
develop
complet
new
system
may
acceler
quantiti
qualiti
util
antibodi
respons
profil
infecti
agent
